These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 18698245

  • 1. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S, Lipscomb J, Eason J.
    Transplantation; 2008 Aug 15; 86(3):418-22. PubMed ID: 18698245
    [Abstract] [Full Text] [Related]

  • 2. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.
    Transplant Proc; 2011 Dec 15; 43(10):3824-8. PubMed ID: 22172854
    [Abstract] [Full Text] [Related]

  • 3. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.
    Am J Gastroenterol; 2005 Nov 15; 100(11):2447-52. PubMed ID: 16279899
    [Abstract] [Full Text] [Related]

  • 4. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
    Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Habrecht O, Settmacher U.
    Transplantation; 2008 Aug 15; 86(3):469-73. PubMed ID: 18698252
    [Abstract] [Full Text] [Related]

  • 5. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.
    J Hepatol; 2005 Jul 15; 43(1):53-9. PubMed ID: 15876467
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul 15; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 7. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA.
    Liver Transpl; 2006 Dec 15; 12(12):1805-12. PubMed ID: 17133585
    [Abstract] [Full Text] [Related]

  • 8. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T.
    Transplantation; 2010 Sep 27; 90(6):661-5. PubMed ID: 20110853
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul 27; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 10. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S, Lyden E.
    Hepatogastroenterology; 2006 Jul 27; 53(70):561-5. PubMed ID: 16995462
    [Abstract] [Full Text] [Related]

  • 11. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2002 Nov 27; 8(11):1000-6. PubMed ID: 12424712
    [Abstract] [Full Text] [Related]

  • 12. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
    Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J, Zoulim F, Trepo C.
    Transplantation; 2005 Feb 15; 79(3):325-9. PubMed ID: 15699763
    [Abstract] [Full Text] [Related]

  • 13. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F, Al-Khaldi J, Asker H, Al-Ajmi M, Owayed S, Varghese R, Siddique I, Al-Nakib B.
    Antivir Ther; 2004 Aug 15; 9(4):499-503. PubMed ID: 15456080
    [Abstract] [Full Text] [Related]

  • 14. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.
    Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, Khaled AS, Bejarano PA, Safdar K, Hill MA, Tzakis AG, Schiff ER.
    Liver Transpl; 2004 May 15; 10(5):595-8. PubMed ID: 15108250
    [Abstract] [Full Text] [Related]

  • 15. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
    Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D.
    J Hepatol; 2012 Sep 15; 57(3):564-71. PubMed ID: 22613001
    [Abstract] [Full Text] [Related]

  • 16. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N, Giannelli G, Antonaci A, Antonaci S.
    J Viral Hepat; 2008 Apr 15; 15(4):300-4. PubMed ID: 18307592
    [Abstract] [Full Text] [Related]

  • 17. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.
    J Gastrointestin Liver Dis; 2008 Jun 15; 17(2):165-72. PubMed ID: 18568137
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
    Pillai AA, Lee VS, Wang E, Rinella ME, Levitsky J.
    Transplant Proc; 2010 Nov 15; 42(9):3647-51. PubMed ID: 21094833
    [Abstract] [Full Text] [Related]

  • 19. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
    Mukherjee S, Lyden E.
    Liver Int; 2006 Jun 15; 26(5):529-35. PubMed ID: 16761996
    [Abstract] [Full Text] [Related]

  • 20. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
    Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, Adeleine P, Trépo C, French Multicenter Group.
    J Hepatol; 2006 Mar 15; 44(3):484-90. PubMed ID: 16426697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.